Ciba Specialty Chemicals Corporation

Solvias Ag

Ciba Specialty Chemicals Corpation

Claudia Marcolli

Martin Szelagiewicz

Paul Adriaan Van Der Schaaf

Andreas Burkhard

Franz Schwarzenbach

Beat Freiermuth

Heinz Wolleb

Annemarie Wolleb

Hans-Jörg Kirner

Fritz Blatter

Hans Jürg Kirner

Paul Van Der Schaaf

Urs Christoph Hofmeier

Brigitte Monika Cron-Eckhardt

Peter Koller

Regine Peter

A device includes a support () and at least two seals (), which are arranged in a row and are hermetically fitted into cavities, and protrude from the support laterally with respect to inlet and outlet openings, one end of the support being provided with an inlet opening () and one end being provided with an outlet opening (), and the seals being provided with a least one inlet opening and one outlet opening, and the support containing at least one first channel () which starts at the inlet opening () and is continuous, and is arranged in such a way that it opens into the inlet openings in the side walls of the seals arranged in a row, and one second channel () which starts at the outlet opening and is continuous, and is arranged in such a way that it opens into the outlet openings in the side walls of the seals arranged in a row. The system is suitable for simultaneous multiple studies, in particular with the use of microtitration plates, and physical measurements of the results directly in the containers, for example of a microtitration plate. The multiple studies may be used to perform screening processes to discover and develop polymorphic and pseudorpolymorphic forms, new formulations and suitable crystallisation conditions.

Sealing system with flow channels

Sertraline hydrochloride polymorphic form II is conveniently prepared by adding hydrogen chloride to solution of sertraline free amine in a ketone. In preferred processes, the solution of sertraline free amine seeded with some crystals of polymorphic form II and/or the solution is heated before addition of the hydrogen chloride.

Polymorphic forms of sertraline hydrochloride

Crystalline forms of Venlafaxine hydrochloride were found, referred to hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.

Crystalline forms of venlafaxine hydrochloride

A crystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug. Furthermore, different crystalline forms of sertraline hydrochloride alcohol solvates, crystalline forms of sertraline hydrochloride hydrates, referred to hereinafter as polymorphic form CSC1, a process for the preparation of the amorphous form of sertraline hydrochloride, and different processes for the preparation of polymorphic forms I, II, V, and T1 are disclosed.

A cystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug. Furthermore, different crystalline forms of sertraline hydrochloride alcohol solvates, crystalline forms of sertraline hydrochloride hydrates, referred to hereinafter as polymorphic form CSC1, a process for the preparation of the amorphous form of sertraline hydrochloride, and different processes for the preparation of polymorphic forms I, II, V, and T1 are disclosed.

Crystalline forms of the (3R,5S)- and the (3S,5R)-enantiomers of fluvastatin, referred to as polymorphic Forms A, B1, B2, C, D and E, processes for the preparation of these crystalline forms and pharmaceutical compositions comprising them are disclosed.

Crystalline forms of Fluvastatin sodium

Novel crystalline forms of Fluvastatin sodium hydrates were found, referred to hereinafter as polymorphic Forms C, D, E and F. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms, a process for the preparation of highly crystalline Fluvastatin sodium Form A, and pharmaceutical compositions comprising the crystalline forms.

Growing community of inventors

Zurich, Switzerland

Claudia Marcolli